# GALNS

## Overview
The GALNS gene encodes the enzyme N-acetylgalactosamine-6-sulfatase, a lysosomal sulfatase critical for the degradation of glycosaminoglycans (GAGs) such as keratan sulfate and chondroitin-6-sulfate. This enzyme is essential for cellular homeostasis, as it prevents the accumulation of undegraded GAGs, which can lead to lysosomal storage disorders. The GALNS protein is a homodimeric glycoprotein, characterized by a complex structure with distinct domains and a highly specialized active site that requires post-translational modifications for its catalytic activity (RiveraColón2012The). Mutations in the GALNS gene are associated with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, a condition marked by skeletal abnormalities due to the accumulation of GAGs (Caciotti2015Optimizing; Zanetti2021Molecular). Understanding the structure and function of GALNS is crucial for developing therapeutic strategies, such as enzyme replacement therapy, to manage this disorder (Zanetti2021Molecular).

## Structure
The GALNS protein is a homodimeric glycoprotein, with each monomer consisting of three distinct domains. The N-terminal domain (residues 28-379) contains the active site and exhibits an α/β topology, featuring a core ten-stranded β-sheet surrounded by six α-helices (RiveraColón2012The). The second domain (residues 380-481) is characterized by a four-stranded antiparallel β-sheet perpendicular to a long α-helix. The C-terminal meander (residues 482-510) threads back into the N-terminal domain, contributing to the active site (RiveraColón2012The).

The active site of GALNS is located in a pocket at the center of the N-terminal α/β domain and includes key residues such as Asp 39, Asp 40, Arg 83, and others, with a Ca²⁺ ion coordinated by these residues (RiveraColón2012The). The enzyme undergoes post-translational modifications, including the conversion of Cys 79 into a formylglycine aldehyde, which is crucial for its catalytic activity (RiveraColón2012The). GALNS also has two N-linked glycosylation sites at Asn 204 and Asn 423, and three disulfide bonds (RiveraColón2012The). The dimer interface buries 3094 Å² of surface area, indicating a significant interaction between the monomers (RiveraColón2012The).

## Function
The GALNS gene encodes the enzyme N-acetylgalactosamine-6-sulfatase, which plays a crucial role in the degradation of glycosaminoglycans (GAGs) such as keratan sulfate and chondroitin-6-sulfate within lysosomes. This enzyme is responsible for removing sulfate groups from these GAGs, a process essential for their breakdown and recycling in healthy human cells (RiveraColón2012The). The active site of GALNS is characterized by a high concentration of basic residues, which creates a positive electrostatic surface potential suitable for binding highly sulfated substrates (RiveraColón2012The).

In healthy cells, GALNS functions to maintain cellular homeostasis by preventing the accumulation of undegraded GAGs, which can otherwise lead to lysosomal storage disorders (RiveraColón2012The). The enzyme's activity is non-redundant, meaning that its function cannot be compensated by other sulfatases in the lysosome (RiveraColón2012The). The enzyme is a homodimeric glycoprotein, and its activity is dependent on a formylglycine modification at residue 79, which is essential for its enzymatic function (RiveraColón2012The). The presence of calcium in the active site is critical for stabilizing the nucleophile and facilitating the cleavage of sulfate groups from substrates (RiveraColón2012The).

## Clinical Significance
Mutations in the GALNS gene lead to mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, a lysosomal storage disorder. This condition is characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulfatase, resulting in the accumulation of glycosaminoglycans such as keratan sulfate and chondroitin-6-sulfate in lysosomes. The buildup of these substances primarily affects cartilage, leading to skeletal abnormalities, including short trunk dwarfism, pectus carinatum, kyphoscoliosis, and joint hypermobility (Tüysüz2019Mutation; Caciotti2015Optimizing; Zanetti2021Molecular).

MPS IVA presents a wide spectrum of clinical severity, ranging from severe forms with early onset and rapid progression to milder, attenuated forms with later onset and slower progression. Severe cases often result in significant skeletal dysplasia and reduced life expectancy, while attenuated cases may have a nearly normal lifespan (Tüysüz2019Mutation; Zanetti2021Molecular). Over 300 mutations in the GALNS gene have been identified, contributing to the clinical variability observed in patients (Tomatsu2005Mutation; Zanetti2021Molecular).

Enzyme replacement therapy with elosulfase alfa is available for managing MPS IVA, aiming to improve endurance and quality of life. Early diagnosis and intervention are crucial for optimizing treatment outcomes (Tüysüz2019Mutation; Zanetti2021Molecular).

## Interactions
The GALNS protein, encoded by the GALNS gene, is involved in several critical interactions within the lysosome. It participates in a lysosomal complex with β-galactosidase, sialidase-1, and protective protein/cathepsin A (PPCA), which are essential for its function (RiveraColón2012The). GALNS also forms a homodimer, which is crucial for its function in transcription regulation. The interaction zone of the GALNS homodimer consists of residues that form a pore-like circular interface, including anti-parallel beta sheets and alpha helices. This dimerization is essential for the protein's stability and function (Selvam2022Molecular).

The enzyme's activity is dependent on post-translational modifications by the enzyme SUMF1, highlighting a significant protein-protein interaction necessary for GALNS's functional activity (Davidson2024Evaluation). Additionally, GALNS interacts with pharmacological chaperones such as ezetimibe and pranlukast, which can modulate its activity and stability. These compounds act as weak competitors, interacting with the active site of GALNS and potentially enhancing its therapeutic efficacy (AlmécigaDiaz2019Identification). These interactions are crucial for the enzyme's role in lysosomal function and the pathogenesis of related disorders.


## References


[1. (AlmécigaDiaz2019Identification) Carlos J. Alméciga-Diaz, Oscar A. Hidalgo, Sergio Olarte-Avellaneda, Alexander Rodríguez-López, Esteban Guzman, Rafael Garzón, Luisa Natalia Pimentel-Vera, María Alejandra Puentes-Tellez, Andrés Felipe Rojas-Rodriguez, Kirill Gorshkov, Rong Li, and Wei Zheng. Identification of ezetimibe and pranlukast as pharmacological chaperones for the treatment of the rare disease mucopolysaccharidosis type iva. Journal of Medicinal Chemistry, 62(13):6175–6189, June 2019. URL: http://dx.doi.org/10.1021/acs.jmedchem.9b00428, doi:10.1021/acs.jmedchem.9b00428. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.9b00428)

[2. (Zanetti2021Molecular) Alessandra Zanetti, Francesca D’Avanzo, Moeenaldeen AlSayed, Ana Carolina Brusius‐Facchin, Yin‐Hsiu Chien, Roberto Giugliani, Emanuela Izzo, David C. Kasper, Hsiang‐Yu Lin, Shuan‐Pei Lin, Laura Pollard, Akashdeep Singh, Rodolfo Tonin, Tim Wood, Amelia Morrone, and Rosella Tomanin. Molecular basis of mucopolysaccharidosis iva (morquio a syndrome): a review and classification of galns gene variants and reporting of 68 novel variants. Human Mutation, 42(11):1384–1398, August 2021. URL: http://dx.doi.org/10.1002/humu.24270, doi:10.1002/humu.24270. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.24270)

[3. (Tüysüz2019Mutation) Beyhan Tüysüz, Dilek Uludağ Alkaya, Güven Toksoy, Nilay Güneş, Timur Yıldırım, İlhan Avni Bayhan, and Zehra Oya Uyguner. Mutation spectrum and pivotal features for differential diagnosis of mucopolysaccharidosis iva patients with severe and attenuated phenotype. Gene, 704:59–67, July 2019. URL: http://dx.doi.org/10.1016/j.gene.2019.04.026, doi:10.1016/j.gene.2019.04.026. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2019.04.026)

[4. (Selvam2022Molecular) Pavalan Selvam, Angita Jain, Jessica Abbott, Abhimanyu S. Ahuja, Anvir Cheema, Katelyn A. Bruno, Herjot Atwal, Irman Forghani, Thomas Caulfield, and Paldeep S. Atwal. Molecular modeling and phenotypic description of a patient with a novel exonic deletion of &lt;b&gt;&lt;i&gt;galns&lt;/i&gt;&lt;/b&gt; with resultant morquio syndrome with two successful pregnancies. Molecular Syndromology, pages 1–8, March 2022. URL: http://dx.doi.org/10.1159/000519326, doi:10.1159/000519326. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000519326)

5. (Davidson2024Evaluation) Evaluation of Select Publicly Available in Silico Methods for Predicting Functional Effects of Missense Mutations in the GALNS Gene. This article has 0 citations.

[6. (Tomatsu2005Mutation) Shunji Tomatsu, Adriana M. Montaño, Tatsuo Nishioka, Monica A. Gutierrez, Olga M. Peña, Georgeta G. Tranda firescu, Patricia Lopez, Seiji Yamaguchi, Akihiko Noguchi, and Tadao Orii. Mutation and polymorphism spectrum of the galns gene in mucopolysaccharidosis iva (morquio a). Human Mutation, 26(6):500–512, December 2005. URL: http://dx.doi.org/10.1002/humu.20257, doi:10.1002/humu.20257. This article has 130 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20257)

[7. (RiveraColón2012The) Yadilette Rivera-Colón, Emily K. Schutsky, Adriana Z. Kita, and Scott C. Garman. The structure of human galns reveals the molecular basis for mucopolysaccharidosis iv a. Journal of Molecular Biology, 423(5):736–751, November 2012. URL: http://dx.doi.org/10.1016/j.jmb.2012.08.020, doi:10.1016/j.jmb.2012.08.020. This article has 92 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2012.08.020)

[8. (Caciotti2015Optimizing) Anna Caciotti, Rodolfo Tonin, Miriam Rigoldi, Lorenzo Ferri, Serena Catarzi, Catia Cavicchi, Elena Procopio, Maria Alice Donati, Anna Ficcadenti, Agata Fiumara, Rita Barone, Livia Garavelli, Maja Di Rocco, Mirella Filocamo, Daniela Antuzzi, Maurizio Scarpa, Sean D. Mooney, Biao Li, Anastasia Skouma, Sebastiano Bianca, Daniela Concolino, Rosario Casalone, Elena Monti, Marilena Pantaleo, Sabrina Giglio, Renzo Guerrini, Rossella Parini, and Amelia Morrone. Optimizing the molecular diagnosis of galns: novel methods to define and characterize morquio-a syndrome-associated mutations. Human Mutation, 36(3):357–368, March 2015. URL: http://dx.doi.org/10.1002/humu.22751, doi:10.1002/humu.22751. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22751)